Lysis syndrome during therapy of visceral leishmaniasis

Infection

Volumn 40, Issue 2, 2012, Pages 121-123

  Liberopoulos, E N ^a   Kei, A A ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Hyperphosphatemia; Hyperuricemia; Renal failure; Tumor lysis syndrome; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; CALCIUM; CREATININE; MAGNESIUM; NITROGEN; PHOSPHATE; POTASSIUM; UREA; URIC ACID;

ADULT; AGED; ALKALINIZATION; ANTIBODY TITER; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CONVALESCENCE; CREATININE BLOOD LEVEL; DISEASE PREDISPOSITION; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAGNESIUM BLOOD LEVEL; MALE; OUTCOME ASSESSMENT; PARASITE LOAD; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; TREATMENT DURATION; TUMOR LYSIS SYNDROME; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VISCERAL LEISHMANIASIS;

ADULT; AGED; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; HYPERPHOSPHATEMIA; HYPERURICEMIA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; STATISTICS AS TOPIC; TUMOR LYSIS SYNDROME; YOUNG ADULT;

EID: 84863196993     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-011-0202-9     Document Type: Article

References (13)

1. Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol. 1993;13:273-80. (Pubitemid 23144159)
2. Jeha S. Tumor lysis syndrome. Semin Hematol. 2001;38:4-8. (Pubitemid 33070172)
3. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206-12.
4. Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis. 2010;14:e1032-9.
5. Daher EF, Evangelista LF, Silva Junior GB, et al. Clinical presentation and renal evaluation of human visceral leishmaniasis (kala-azar): a retrospective study of 57 patients in Brazil. Braz J Infect Dis. 2008;12:329-32.
6. Delgado J, Macias J, Pineda JA, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg. 1999;61:766-9.
7. Liberopoulos E, Alexandridis G, Elisaf M. A tumor lysis-like syndrome during therapy of visceral leishmaniasis. Ann Clin Lab Sci. 2002;32:419-21. (Pubitemid 35340450)
8. MDRD GFR calculator. Available fromhttp://www.nephron.com/MDRD-GFR.cgi Last assessed 3 Sep, 2011.
9. Hurley JC. Antibiotic-induced release of endotoxin: a reappraisal. Clin Infect Dis. 1992;15:840-54.
10. Hsu HH, Chan YL, Huang CC. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol. 2004;17:50-6.
11. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-54. (Pubitemid 38452647)
12. Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010;89:236-44.
13. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362:504-12.